Hypoglycemia From Residual Insulin – Ever Heard of It?
New technology from Monarch Medical Technologies statistically eliminates severe hypoglycemia in hospital glucose management.
Monarch Medical Technologies, a company committed to providing the safest insulin dosing software, is proud to announce their EndoTool’s groundbreaking, patent-pending Estimated Residual Extracellular Insulin (EREI) technology for any hospital unit where intravenous (IV) insulin is used. Similar to the “insulin-on-board” condition associated with subcutaneous insulin administration, EREI refers to residual insulin from intravenous insulin therapy present in a patient’s body that has potential for future activity affecting blood glucose levels.
“This technology provides additional safety to a patient’s intravenous insulin dosing, creating the potential to eliminate severe hypoglycemia, excluding human error,” says Dr. Patrick Burgess, Founder and Inventor of EndoTool, at Monarch Medical Technologies.
Every patient who receives IV insulin in a hospital requires a personalized dose based on their individual response to insulin dosing, kidney function, current medical treatment, meals consumed, and stress level among many other variables. As a result, the pancreas must constantly modify the production of insulin. The amount of residual extracellular insulin present in a person’s body is an important variable that must be considered in order to achieve correct insulin dosing, maintain glucose control, and avoid hypoglycemia.
Contingent on a patient’s kidney function along with current and historical response to insulin, EndoTool IV predicts and adjusts a patient’s subsequent dose to prevent a hypoglycemic event. If a patient has more residual insulin than can be supported by circulating glucose, the software further adapts dosing recommendations, and if desired, recommends a counter-balancing dextrose dose.
As displayed in the diagram below, the overall outcome for BG levels for patients on EndoTool IV (measured in patient days) surpasses the overall result as compared to patient data from the Yale Glucometrics database.
(Post NICE SUGAR Study)
|High Blood Glucose (>300 mg/dL)||7.90%||2.30%|
|Low Blood Glucose (<70 mg/dL)||5.90%||3.20%|
|Low Blood Glucose (<40 mg/dL)||0.70%||0.12%|
|*All data collected through Monarch Medical Technologies internal customer analysis.
**>70% of patients using EndoTool IV with EREI had a goal range of 100-140 mg/dL vs. Yale Glucometrics database is exclusively a goal range of 140-180 mg/dL.
EndoTool’s new functionality not only improves glucose control and reduces the risk of hypoglycemia, it provides confidence for the caregiver. Residual insulin in the body is dangerous, and often the culprit of increased risk for hypoglycemia-related morbidity and mortality. At last, caregivers have a safer option for dosing insulin to provide a better standard of care.
About Monarch Medical Technologies
Monarch Medical Technologies is the leading provider of clinical decision support software for inpatient glucose management and the emerging leader as the world’s safest prescriptive drug dosing platform. With over 60 combined algorithms developed by a team of practicing doctors and mathematicians, Monarch’s EndoTool Glucose Management System ensures that dosing is individualized and responsive to ongoing changes in each patient’s unique physiological response. As a Class II FDA-cleared software suite, EndoTool allows hospitals and care providers to dose insulin safely by replacing antiquated and dangerous linear, point-to-point, or sliding scale formulas. This technology is doing more than changing the conversation in over 180 hospitals— it’s helping providers achieve the coveted Triple Aim of better health, better care, at a lower cost.